CureMetrix Products

Our Technology

CureMetrix is dedicated to developing the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Our FDA-cleared and pipeline products span BAC detection and localization, quantification, contextualization, workflow optimization, cancer detection, and breast density analysis.

cmAngio Scorecard
FDA Cleared

cmAngio®

Detects, Quantifies, and Contextualizes

First and only FDA-cleared AI that detects, quantifies, and contextualizes Breast Arterial Calcifications (BAC) from routine screening mammograms. cmAngio® provides objective BAC extent measurements, age-based contextualization through the CureMetrix Reference Library, enhanced scorecards, and FHIR-enabled interoperability—all from the mammogram already being performed.

  • Age-based BAC Percentile and Age-based BAC Prevalence allow contextualization for patient management related to age-matched peers.
  • BAC length measurements (View-level BAC Length and Study-level BAC Length) allow for consistent and reliable contextualization of BAC extent (detected BAC findings) facilitating patient management.
  • cmAngio is generalizable to Hologic and GE Systems, allowing broader adoption of this AI tool.
Request Demo
cmTriage
FDA Cleared

cmTriage®

Mammography Workflow Optimization AI

The First FDA-cleared AI tool for mammography workflow optimization. cmTriage enables radiologists to prioritizes mammography cases, flagging suspicious findings for immediate radiologist review and reducing turnaround time for critical cases.

  • Works across all breast densities
  • Integration with existing PACS systems
  • Works with both mass and calcifications
  • Full audit trail and reporting
  • FDA 510(k) clearance: K183285; ANVISA Notification 81464750075
Request Demo
cmAssist
In Development

cmAssist®

Cancer Detection Scoring AI

Provides radiologists with AI-powered detection support, highlighting regions of interest on mammography images and offering confidence scores for each finding. Improves radiologist performance.

  • Lesion localization and bounding
  • Searches all views of a 2D mammogram for abnormal areas of density, mass, or calcification
  • Confidence scoring per finding
  • Classifies anomalies as suspicious or verifiable benign
cmDensity
In Development

cmDensity™

Automated Breast Density Analysis

An artificial intelligence (AI) based detection software that helps radiologists classify density accurately and consistently.

  • BI-RADS classification, automated
  • Fewer errors, greater efficiency
  • Consistent results, less reader variability
  • Pre-populated, clearer reports

Disclaimer: FDA 510(k) K250754 and K260980 — cmAngio AI-based software for breast arterial calcification detection and localization. Performance data on file. cmAngio is FDA-cleared for commercial use in the U.S. cmTriage is FDA-cleared for commercial use in the U.S and ANVISA-cleared for commercial use in Brazil. cmAssist is under development in the U.S and ANVISA-cleared for commercial use in Brazil. cmDensity is under development and is not available for commercial use in any country.